Invesco Developing Markets Fund, a long-term fund, led a $155m Series C funding round in Brii Biosciences, a biotechnology company. Additional investors include GIC, Lake Bleu Capital and three current investors. “Since our founding in 2018, Brii Bio has made tremendous progress toward our mission to accelerate the development and delivery of breakthrough medicines through partnerships and our own insight in highly differentiated medicine discovery. As we work to address some of the world’s biggest public health issues and disease burdens, we are pleased and honored to have the support of investors who share our mission to discover, develop and deliver innovative treatments for patients not only in China, but throughout the world," Zhi Hong, Brii Bio CEO.